Codice QR

MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer

Summary: The introduction of immunotherapy as a first-line treatment for advanced small cell lung cancer (SCLC) represents significant progress, yet there remains an opportunity to further improve patient outcomes. Hepatocyte growth factor (HGF) receptor (MET) pathway activation promotes epithelial-...

Descrizione completa

Salvato in:
Autori principali: Raúl del Rey-Vergara, Miguel Alejandro Galindo-Campos, Pedro Rocha, Marina Carpes, Carlos Martínez, Laura Masfarré, Silvia Menéndez, Fabricio Quimis, Adrià Rossell, Albert Iñañez, Sandra Pérez-Buira, Federico Rojo, Ramon Gimeno, Dolores Isla, Jon Zugazagoitia, Cristina Martí Blanco, Rosario García-Campelo, Alberto Moreno-Vega, Luis León-Mateos, Ángel Callejo Mellén, Kwon-Sik Park, Simon Heeke, John V. Heymach, Álvaro Taus, Luis Paz-Ares, Ana Rovira, Edurne Arriola
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2025-07-01
Serie:Cell Reports Medicine
Soggetti:
small cell lung cancer
MET inhibitor
immune checkpoint inhibitor
epithelial-mesenchymal transition
myeloid-derived suppressor cells
Accesso online:http://www.sciencedirect.com/science/article/pii/S2666379125002678
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi